CorMedix to acquire Heron Therapeutics assets, reports Q3 2026 results
CorMedix disclosed on November 12, 2026 that it agreed on November 9 to buy substantially all of Heron's assets, alongside third-quarter revenue of $54.5 million.
SEC filing (2)
6 stories
CorMedix disclosed on November 12, 2026 that it agreed on November 9 to buy substantially all of Heron's assets, alongside third-quarter revenue of $54.5 million.
SEC filing (2)
The deal brings four commercial drugs into CorMedix's hospital business for $145 million cash plus stock, with Heron staying public to pursue new ventures.
SEC filing (3)
The company said topline interim results from its pivotal FORTIFI-HN01 study are expected in mid-2027, while cash on hand is projected to fund operations into the first half of 2029.
SEC filing (10)
CorMedix cited a new CMS final rule setting a $8.32 per-session Q1 2027 add-on for DefenCath, and said it expects the rate to dip in Q2 before rising later in the year.
SEC filing
The agency set a first-quarter 2027 PDUFA date for the antifungal's new prophylaxis use, based on the Phase III ReSPECT trial.
SEC filing
Actinium Pharmaceuticals said Matt David, who previously served as CFO and chief business officer at CorMedix, began as CFO on October 14, 2026.
SEC filing